Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004 PALO ALTO, Calif. and MIAMI, June 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...

Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform HOUSTON and SHANGHAI, April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with...

WX DEADLINE ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against WuXi PharmaTech (Cayman) Inc. – WX NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of WuXi PharmaTech (Cayman) Inc. (NYSE: WX)...

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against WuXi PharmaTech (Cayman) Inc. – WX NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of WuXi PharmaTech (Cayman) Inc....

ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against WuXi PharmaTech (Cayman) Inc. – WX NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of WuXi PharmaTech (Cayman) Inc. (NYSE: WX)...